Atticus Wealth Management LLC Has $1.22 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Atticus Wealth Management LLC trimmed its position in Johnson & Johnson (NYSE:JNJ) by 6.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,695 shares of the company’s stock after selling 505 shares during the period. Atticus Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,217,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Foguth Wealth Management LLC. acquired a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $329,000. Brown Miller Wealth Management LLC raised its position in shares of Johnson & Johnson by 3.0% in the 1st quarter. Brown Miller Wealth Management LLC now owns 18,822 shares of the company’s stock valued at $2,977,000 after acquiring an additional 542 shares during the period. Winthrop Advisory Group LLC raised its position in shares of Johnson & Johnson by 9.1% in the 1st quarter. Winthrop Advisory Group LLC now owns 9,456 shares of the company’s stock valued at $1,496,000 after acquiring an additional 788 shares during the period. Coston McIsaac & Partners raised its position in shares of Johnson & Johnson by 2.3% in the 1st quarter. Coston McIsaac & Partners now owns 34,156 shares of the company’s stock valued at $5,402,000 after acquiring an additional 774 shares during the period. Finally, Vicus Capital raised its position in shares of Johnson & Johnson by 13.8% in the 1st quarter. Vicus Capital now owns 7,076 shares of the company’s stock valued at $1,119,000 after acquiring an additional 856 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Trading Up 0.2 %

JNJ stock opened at $146.16 on Monday. The stock has a market cap of $351.76 billion, a price-to-earnings ratio of 9.11, a price-to-earnings-growth ratio of 2.43 and a beta of 0.53. The company has a fifty day moving average price of $148.14 and a two-hundred day moving average price of $154.05. Johnson & Johnson has a one year low of $143.13 and a one year high of $175.97. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. The business had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. Johnson & Johnson’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.68 earnings per share. Equities analysts anticipate that Johnson & Johnson will post 10.62 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.39%. The ex-dividend date of this dividend was Monday, May 20th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s payout ratio is 30.92%.

Wall Street Analysts Forecast Growth

Several analysts have commented on JNJ shares. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Thursday, June 20th. Morgan Stanley dropped their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 17th. Royal Bank of Canada restated an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a report on Monday, June 17th. Bank of America dropped their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Finally, The Goldman Sachs Group began coverage on shares of Johnson & Johnson in a report on Thursday, May 30th. They set a “neutral” rating and a $160.00 target price on the stock. Eight research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $174.07.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.